Evidence map›Paper›PMID 42196390›Full record

ReviewInternational journal of molecular sciences2026

Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.

Ehab Takrori, Mahmoud Abdulmajid, Deepthi Devagudi, Ramsha Sohail, Zaynah Sadiq, Chris Berneau, Andrew Shenouda, Rakesh Adelli, Supriya Peshin, Sakshi Singal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ehab TakroriCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0009-0009-9062-9761
Mahmoud AbdulmajidSchool of Medicine, University of Jordan, Amman 11942, Jordan.
Deepthi DevagudiDepartment of Hospital Medicine, Adventist Health, Hanford, CA 93230, USA.
Ramsha SohailDepartment of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
Zaynah SadiqWashington Health, Fremont, CA 94538, USA.
Chris BerneauDepartment of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
Andrew ShenoudaDepartment of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
Rakesh AdelliCenter for Applied Research and Evaluation in Women's Health, Department of Health Services Management & Policy, East Tennessee State University, Johnson City, TN 37614, USA.ORCID 0009-0005-4516-7626
Supriya PeshinDepartment of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.ORCID 0000-0002-3895-9474
Sakshi SingalDepartment of Hematology & Oncology, East Tennessee State University, Johnson City, TN 37604, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs) remain highly lethal gastrointestinal malignancies because of late presentation, marked molecular heterogeneity, and limited durable benefit from conventional systemic therapy. This narrative review summarizes recent advances in both diseases, focusing on practice-informing clinical trials, biomarker-driven treatment strategies, and translational insights into tumor biology and resistance. In PDAC, progress includes refinement of perioperative management, broader germline and somatic testing, recognition of DNA damage repair-deficient subsets, and development of KRAS-directed therapies and rational combination strategies. In BTCs, especially intrahepatic cholangiocarcinoma, comprehensive molecular profiling has expanded precision oncology through actionable alterations such as

Indexed as

Biliary Tract NeoplasmsBiomarkers, TumorCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansImmunotherapyMolecular Targeted TherapyBiomarkers, Tumorantibody–drug conjugatesbiliary tract cancersbiomarkerscholangiocarcinomagallbladder cancerimmunotherapymolecular profilingpancreatic ductal adenocarcinomaprecision oncologytargeted therapytreatment sequencingtumor microenvironment

Identifiers

PMID42196390
PMCPMC13207714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.